T1	Condition 0 23	Acute coronary syndrome
T2	Condition 25 28	ACS
T3	Temporal 30 45	within 3 months
T4	Drug 54 66	beta-blocker
T5	Temporal 77 97	for the last 2 weeks
R1	Subsumes Arg1:T1 Arg2:T2	
R2	Has_temporal Arg1:T1 Arg2:T3	
R3	Has_temporal Arg1:T4 Arg2:T5	
T6	Drug 165 209	Non-dihydropyridine calcium channel blockers
T7	Drug 211 220	NDHP-CCBs
R4	Subsumes Arg1:T6 Arg2:T7	
T8	Drug 225 235	ivabradine
T9	Temporal 236 256	for the last 2 weeks
T10	Drug 264 271	Digoxin
T11	Multiplier 283 292;297 312	more than 0.125 milligram
T12	Value 294 295;297 302;314 316	> 0.125 mg
R5	Subsumes Arg1:T11 Arg2:T12	
R6	Has_multiplier Arg1:T10 Arg2:T11	
*	OR T6 T8
T13	Scope 165 235	Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine
R7	Has_temporal Arg1:T13 Arg2:T9	
T14	Non-query-able 100 158	Under other medicine treatment which may affect heart rate
T15	Condition 334 342	Diabetes
T16	Qualifier 321 333	Uncontrolled
R8	Has_qualifier Arg1:T15 Arg2:T16	
T17	Measurement 344 358	hemoglobin A1c
T18	Measurement 361 366	HbA1c
T19	Value 368 373	>7.5%
R9	Subsumes Arg1:T17 Arg2:T18	
R10	Has_value Arg1:T17 Arg2:T19	
R11	AND Arg1:T15 Arg2:T17	
T20	Condition 400 412	hypertension
T21	Qualifier 387 399	uncontrolled
T22	Qualifier 377 383	Severe
*	OR T22 T21
T23	Scope 377 399	Severe or uncontrolled
R12	Has_scope Arg1:T20 Arg2:T23	
T24	Measurement 422 445	Systolic Blood Pressure
T25	Measurement 447 450	SBP
T26	Value 452 479	>180 millimeters of mercury
T27	Value 452 456;481 485	>180 mmHg
R13	Subsumes Arg1:T26 Arg2:T27	
T28	Measurement 499 523	Diastolic Blood Pressure
T29	Measurement 525 528	DBP
T30	Value 530 538	>110mmHg
T31	Temporal 539 558	at screening period
T32	Reference_point 542 551	screening
R14	Has_index Arg1:T31 Arg2:T32	
R15	Subsumes Arg1:T28 Arg2:T29	
R16	Has_value Arg1:T28 Arg2:T30	
T33	Qualifier 491 498	resting
R17	Has_qualifier Arg1:T28 Arg2:T33	
R18	Subsumes Arg1:T24 Arg2:T25	
R19	Has_value Arg1:T24 Arg2:T26	
T34	Qualifier 414 421	resting
R20	Has_qualifier Arg1:T24 Arg2:T34	
T35	Scope 414 558	resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period
R21	Has_scope Arg1:T20 Arg2:T35	
*	OR T24 T28
T36	Scope 414 538	resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg
R22	Has_temporal Arg1:T36 Arg2:T31	
T37	Condition 569 580	hypotension
T38	Qualifier 562 568	Severe
T39	Measurement 590 593	SBP
T40	Value 594 603;608 614	less than 90mmHg
T41	Qualifier 582 589	resting
T42	Qualifier 619 626	resting
T43	Measurement 627 630	DBP
T44	Value 630 637	<50mmHg
R23	Has_value Arg1:T43 Arg2:T44	
R24	Has_qualifier Arg1:T43 Arg2:T42	
R25	Has_value Arg1:T39 Arg2:T40	
R26	Has_qualifier Arg1:T39 Arg2:T41	
*	OR T39 T43
R27	Has_qualifier Arg1:T37 Arg2:T38	
T45	Scope 582 637	resting SBP less than (<) 90mmHg, or resting DBP<50mmHg
R28	Has_scope Arg1:T37 Arg2:T45	
T46	Measurement 649 659	heart rate
T47	Qualifier 641 648	Resting
T48	Value 660 679	<60 beat per minute
T49	Value 660 663;681 684	<60 bpm
R29	Subsumes Arg1:T48 Arg2:T49	
R30	Has_qualifier Arg1:T46 Arg2:T47	
R31	Has_value Arg1:T46 Arg2:T48	
T50	Drug 709 719	Bisoprolol
T51	Condition 692 705	contradiction
R32	AND Arg1:T51 Arg2:T50	
T52	Condition 752 771	Acute heart failure
T53	Condition 794 822	heart failure decompensation
T54	Procedure 833 862	intravenous inotropic therapy
R33	AND Arg1:T53 Arg2:T54	
*	OR T52 T53
T55	Condition 865 882	Cardiogenic shock
T56	Condition 885 917;927 933	Atrioventricular block of second degree
T57	Condition 885 910;921 933	Atrioventricular block of third degree
*	OR T57 T56
T58	Device 945 954	pacemaker
T59	Negation 935 942	without
R34	Has_negation Arg1:T58 Arg2:T59	
T60	Condition 958 977	Sick sinus syndrome
T61	Condition 980 996	Sinoatrial block
T62	Condition 1006 1016	heart rate
T63	Qualifier 999 1005	Slowed
R35	Has_qualifier Arg1:T62 Arg2:T63	
T64	Condition 1048 1059	bradycardia
T65	Qualifier 1036 1047	symptomatic
T66	Condition 1026 1034	symptoms
R36	AND Arg1:T62 Arg2:T66	
R37	Subsumes Arg1:T62 Arg2:T64	
R38	Has_qualifier Arg1:T64 Arg2:T65	
T67	Condition 1073 1087	blood pressure
T68	Qualifier 1063 1072	Decreased
R39	Has_qualifier Arg1:T67 Arg2:T68	
T69	Condition 1097 1105	symptoms
R40	AND Arg1:T67 Arg2:T69	
T70	Condition 1119 1130	hypotension
T71	Qualifier 1107 1118	symptomatic
R41	Has_qualifier Arg1:T70 Arg2:T71	
R42	Subsumes Arg1:T67 Arg2:T70	
T72	Condition 1141 1157	bronchial asthma
T73	Qualifier 1134 1140	Severe
T74	Condition 1168 1205	chronic obstructive pulmonary disease
T75	Qualifier 1161 1167	severe
R43	Has_qualifier Arg1:T74 Arg2:T75	
R44	Has_qualifier Arg1:T72 Arg2:T73	
*	OR T72 T74
T76	Condition 1223 1260	peripheral arterial occlusive disease
T77	Condition 1265 1283	Raynaud's syndrome
T78	Qualifier 1208 1213	Sever
T79	Scope 1223 1283	peripheral arterial occlusive disease and Raynaud's syndrome
T80	Non-query-able 1261 1264	and
*	OR T76 T77
R45	Has_qualifier Arg1:T79 Arg2:T78	
T81	Condition 1296 1313	phaeochromocytoma
T82	Qualifier 1286 1295	Untreated
R46	Has_qualifier Arg1:T81 Arg2:T82	
T83	Condition 1316 1334	Metabolic acidosis
T84	Condition 1337 1353	Hypersensitivity
T85	Drug 1357 1367	bisoprolol
T86	Drug 1385 1395	excipients
T87	Qualifier 1374 1377	any
R47	Has_qualifier Arg1:T86 Arg2:T87	
*	OR T85 T86
T88	Scope 1357 1395	bisoprolol or to any of the excipients
R48	Has_scope Arg1:T84 Arg2:T88	
T89	Condition 1405 1415	Arrhythmia
T90	Qualifier 1398 1404	Severe
T91	Condition 1426 1445	atrial fibrillation
T92	Condition 1447 1461	atrial flutter
T93	Condition 1463 1487	ventricular fibrillation
T94	Condition 1489 1508	ventricular flutter
T95	Condition 1512 1535	ventricular tachycardia
*	OR T91 T92 T93 T94 T95
R49	Has_qualifier Arg1:T89 Arg2:T90	
T96	Scope 1426 1535	atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia
R50	Subsumes Arg1:T89 Arg2:T96	
T97	Condition 1550 1572	valvular heart disease
T98	Qualifier 1538 1549	Significant
T99	Condition 1574 1598	congenital heart disease
T100	Condition 1600 1623	pulmonary heart disease
T101	Condition 1627 1650	perinatal heart disease
*	OR T97 T99 T100 T101
T102	Scope 1550 1650	valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease
R51	Has_qualifier Arg1:T102 Arg2:T98	
T103	Condition 1653 1674	Acute pulmonary edema
T104	Condition 1684 1703	hepatic dysfunction
T105	Qualifier 1677 1683	Severe
R52	Has_qualifier Arg1:T104 Arg2:T105	
T106	Measurement 1718 1748	Serum Alanine Aminotransferase
T107	Measurement 1750 1753	ALT
R53	Subsumes Arg1:T106 Arg2:T107	
T108	Value 1755 1799	> triple the upper limit of the normal range
R54	Has_value Arg1:T106 Arg2:T108	
T109	Non-query-able 1801 1807	and/or
T110	Measurement 1809 1841	Serum Aspartate Aminotransferase
T111	Measurement 1843 1846	AST
R55	Subsumes Arg1:T110 Arg2:T111	
T112	Value 1848 1898	> triple the upper limit of the normal value range
R56	Has_value Arg1:T110 Arg2:T112	
T113	Non-query-able 1899 1905	and/or
*	OR T106 T110
T114	Condition 1914 1931	renal dysfunction
T115	Qualifier 1907 1913	Severe
R57	Has_qualifier Arg1:T114 Arg2:T115	
T116	Measurement 1946 1962	Serum creatinine
T117	Value 1963 2006	> twice the upper limit of the normal range
R58	Has_value Arg1:T116 Arg2:T117	
T118	Condition 2008 2030	Chronic Kidney Disease
T119	Measurement 2032 2058	glomerular filtration rate
T120	Value 2059 2084	<45 Milliliter per minute
R59	Has_value Arg1:T119 Arg2:T120	
R60	AND Arg1:T118 Arg2:T119	
T121	Condition 2088 2103	Hyperthyroidism
T122	Condition 2107 2121	hypothyroidism
*	OR T121 T122
T123	Condition 2131 2149	infectious disease
T124	Qualifier 2124 2130	Severe
R61	Has_qualifier Arg1:T123 Arg2:T124	
T125	Condition 2164 2201	Human Immunodeficiency Virus positive
T127	Condition 2212 2224	tuberculosis
T128	Qualifier 2205 2211	active
R63	Has_qualifier Arg1:T127 Arg2:T128	
*	OR T125 T127
T126	Scope 2164 2224	Human Immunodeficiency Virus positive or active tuberculosis
R62	Subsumes Arg1:T123 Arg2:T126	
T129	Condition 2234 2252	autoimmune disease
T130	Qualifier 2227 2233	Severe
T131	Condition 2259 2278	lupus erythematosus
T132	Condition 2280 2298	multiple sclerosis
*	OR T131 T132
T133	Scope 2259 2298	lupus erythematosus, multiple sclerosis
R64	Subsumes Arg1:T129 Arg2:T133	
R65	Has_qualifier Arg1:T129 Arg2:T130	
T134	Condition 2308 2319;2346 2353	respiratory disease
T135	Condition 2321 2330;2346 2353	digestive disease
T136	Condition 2332 2353	hematological disease
T137	Qualifier 2301 2307	Severe
T138	Scope 2308 2353	respiratory, digestive, hematological disease
*	OR T136 T135 T134
R66	Has_qualifier Arg1:T138 Arg2:T137	
T139	Condition 2365 2371	Anemia
T140	Measurement 2375 2377	Hb
T141	Value 2378 2398	< 100 gram per litre
R67	Has_value Arg1:T140 Arg2:T141	
R68	AND Arg1:T139 Arg2:T140	
R69	Subsumes Arg1:T138 Arg2:T139	
T142	Condition 2403 2408	tumor
*	OR T138 T142
T143	Condition 2423 2439	hypersensitivity
T144	Drug 2443 2453	Bisoprolol
T145	Drug 2469 2478	excipient
T146	Qualifier 2458 2461	any
*	OR T144 T145
R70	Has_qualifier Arg1:T145 Arg2:T146	
T147	Scope 2443 2478	Bisoprolol, or any of the excipient
R71	Has_scope Arg1:T143 Arg2:T147	
T148	Condition 2494 2507	alcohol abuse
T149	Condition 2481 2490;2502 2507	Substance abuse
*	OR T148 T149
T150	Procedure 2519 2540	heart transplantation
T151	Procedure 2544 2566	pacemaker implantation
T152	Procedure 2568 2585	revascularization
T153	Temporal 2596 2611	within 3 months
T154	Mood 2616 2623	plan to
T155	Temporal 2648 2659	in 6 months
*	OR T150 T151 T152 T159
T156	Scope 2519 2585	heart transplantation or pacemaker implantation; revascularization
R72	Has_temporal Arg1:T156 Arg2:T153	
T157	Procedure 2519 2540	heart transplantation
T158	Procedure 2544 2566	pacemaker implantation
T159	Procedure 2568 2585	revascularization
*	OR T157 T158
T160	Scope 2519 2585	heart transplantation or pacemaker implantation; revascularization
R73	Has_mood Arg1:T160 Arg2:T154	
R74	Has_temporal Arg1:T160 Arg2:T155	
*	OR T160 T156
T161	Non-query-able 2662 2753	Currently undertaking other treatment that may affect the safety and/or efficacy evaluation
T162	Drug 2760 2783	beta receptors agonists
T163	Post-eligibility 2797 2841	No legal ability or legal ability is limited
T164	Post-eligibility 2845 2947	ubjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent
T165	Pregnancy_considerations 2950 3042	Child-bearing period women without effective contraceptive measures, pregnancy and lactation
T166	Non-query-able 3045 3108	Participation in another clinical trial within the past 90 days
T167	Post-eligibility 3111 3214	Other significant condition that in the Investigator's opinion would exclude the subject from the trial
